Pediatrix Medical Group, Inc.
NYSE:MDMedical - Care Facilities
-$0.48 today
- Market cap
- $2.41B
- Beta
- 0.70
- P/E (TTM)
- 11.0
- EPS (TTM)
- $2.10
Volume 0.64M
Average 0.82M
MD Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Pediatrix Medical Group, Inc.NYSE: MD
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow grows, but more slowly than its trailing trend
Q3 FY2026 financing cash flow of $89.63M (cash outflow) rose 213.8% year over year, behind the +436.2% change in trailing-twelve-month financing cash flow. Sequentially, it rose 82.8% from the prior quarter. Over 3 fiscal years it compounded at -39.6% a year.
Context
- Financing cash flow amounted to 5.6% of revenue in FY2025, up 4.9 pp from a year earlier.
- Financing cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +213.8% toward the trailing-twelve-month pace of +436.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (107.49M) USD
- Year-over-year change
- -642.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (107.49M) | -642.1% |
| FY2024 | 2024-12-31 | (14.49M) | +43.7% |
| FY2023 | 2023-12-31 | (25.72M) | +94.7% |
| FY2022 | 2022-12-31 | (487.55M) | +35.9% |
| FY2021 | 2021-12-31 | (760.12M) | — |
Financing Cash Flow vs competitors
How MD compares with its peers on the latest reported figures
- MD's LTM Sep 2026 financing cash flow of $234.94M is the 4th largest of the 11 companies compared; the peer median is $51.99M.
- Its year-over-year change of +436.2% is the 5th highest of 11, against a peer median of -41.9%.
- Financing cash flow amounts to 12.0% of revenue for MD, versus a peer median of 3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $597.53M | +3986.4% | — | 16.9% | |
| LTM Sep 2026 | $384.41M | +443.1% | +41.8% | 24.3% | |
| LTM Sep 2026 | $242M | -46.9% | +9.0% | 4.0% | |
| LTM Sep 2026 | $234.94M | +436.2% | -39.6% | 12.0% | |
| LTM Mar 2026 | $166.09M | -58.1% | +67.2% | 3.0% | |
| LTM Jun 2026 | $127.85M | +606.1% | — | 8.1% | |
| LTM Jun 2026 | $106M | -161.1% | +3.3% | 7.2% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $98.85M | -437.4% | -27.4% | 1.5% |
| LTM Oct 2026 | $35.37M | +13650.2% | -55.7% | 1.3% | |
| LTM Sep 2026 | $28.62M | -92.2% | — | 0.8% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $5.13M | -36.8% | -46.0% | 0.4% |
| Peer median (excluding MD) | $51.99M | -41.9% | +3.3% | 3.5% | |
Competitors are the stored peer set for MD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 108.01M | 62.57M | (60.41M) | (99.07M) | 165.39M |
| Depreciation & Amortization | 32.15M | 35.64M | 36.17M | 32.23M | 21.83M |
| Deferred Income Tax | (31.24M) | (22.77M) | 3.24M | (2.13M) | 52.19M |
| Stock-Based Compensation | 18.97M | 16.13M | 12.32M | 11.87M | 18.05M |
| Change in Working Capital | (23.36M) | 31.83M | (11.63M) | 88.24M | 41.83M |
| Accounts Receivables | (72.73M) | (5.54M) | 26.28M | 10.29M | 30.56M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 21.33M | 420K | (11.92M) | 51.14M | 28.33M |
| Other Working Capital | 28.05M | 36.95M | (25.98M) | 26.81M | (17.06M) |
| Other Non-Cash Items | (27.8M) | 43.55M | 157.63M | 175.44M | (28.18M) |
| Operating Cash Flow | 76.74M | 166.94M | 137.33M | 206.57M | 271.09M |
| Capital Expenditures | (32.25M) | (29.71M) | (33.33M) | (22.02M) | (18.46M) |
| Acquisitions (Net) | (29.93M) | (28.17M) | (6.67M) | (8.17M) | 6.8M |
| Purchases of Investments | (35.05M) | (17.35M) | (31.89M) | (64.55M) | (29.85M) |
| Sales of Investments | 16.5M | 16.89M | 22.91M | 52.49M | 26.67M |
| Other Investing Activities | 27.66M | 1.38M | 807K | 6.84M | (3.47M) |
| Investing Cash Flow | (53.07M) | (56.95M) | (48.18M) | (35.41M) | (18.3M) |
| Debt Repayment | (762.66M) | (405.17M) | (19.12M) | (15.39M) | (20.75M) |
| Common Stock Issued | 6.85M | 5.4M | 4.91M | 3.64M | 3.18M |
| Common Stock Repurchased | (4.72M) | (88.51M) | (919K) | (1.7M) | (86.68M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 407K | 732K | (10.59M) | (1.03M) | (3.25M) |
| Financing Cash Flow | (760.12M) | (487.55M) | (25.72M) | (14.49M) | (107.49M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (736.45M) | (377.57M) | 63.43M | 156.68M | 145.3M |
| Free Cash Flow | 44.49M | 137.23M | 104M | 184.55M | 252.63M |
Pediatrix Medical Group, Inc.
NYSE:MD
Intrinsic Alpha fair value
Locked
Current Price
$30.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.